MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), announced that its leadership will present at two notable life sciences conferences in New York. Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present at The Citizens JMP Life Sciences Conference at the New York Hilton Midtown on May 13, 2024. Following this, Dr. Huma Qamar, Chief Medical Officer, will engage in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024.
These presentations will provide insights into Ocugen’s recent business achievements and advancements in gene therapy clinical development, particularly focusing on the OCU400 Phase 3 liMeliGhT clinical trial. OCU400, a groundbreaking modifier gene therapy, stands out as the first of its kind to enter Phase 3 trials with potential treatment for a broad range of retinitis pigmentosa indications.
Attendees and those tuning into the live webcasts can expect detailed updates on Ocugen’s strategic direction and progress in its gene therapy programs. Replays of both presentations will be accessible on the company’s website under the Events section, offering a valuable resource for those interested in Ocugen’s path forward in the biopharmaceutical field.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.